History or known presence of central nervous system metastases.
History of another malignancy except: Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to panitumumab or excipients that contraindicates their participation.
Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g., panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib).
Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy <=30 days before first dose of study treatment or not recovered from any acute toxicity.
Other investigational procedure <=30 days before study entry.
History of interstitial lung disease (ILD) e.g., interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography.
Subject previously enrolled to this study.
History of keratitis, ulcerative keratitis or severe dry eye.
Major surgery (e.g., requiring general anesthesia) <=30 days before first dose of study treatment. Subjects must have recovered from any surgery related toxicities.
Minor surgical procedure (e.g., open biopsy) <=7 days before first dose of study treatment, or not yet recovered from prior minor surgery Note: uncomplicated placement of vascular access device, fine needle aspiration, thoracocentesis or paracentesis >=3 days prior to first dose of study treatment is acceptable.
Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <=6 months prior to enrolment.
History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with the study participation or investigational product administration, compliance with the study procedures or may interfere with the interpretation of the results.
Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event <=30 days before first dose of study treatment. If on anticoagulation, subject must be on stable therapeutic dose prior to first dose of study treatment.
Subject who is pregnant or breast feeding, or planning to become pregnant during treatment and within 2 months after the discontinuation of study treatment.
Known positive test(s) for human immunodeficiency virus infection (testing is not required in the absence of clinical suspicion).
Active infection requiring systemic treatment or any uncontrolled infection <=14 days prior to first dose of study treatment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).
Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures or is unwilling or unable to comply with study requirements.

NCT02301962_exc_T1
Condition
central nervous system metastases
NCT02301962_exc_T2
Qualifier
another
NCT02301962_exc_T3
Condition
malignancy
NCT02301962_exc_T4
Condition
Malignancy
NCT02301962_exc_T5
Procedure
treated with curative intent
NCT02301962_exc_T6
Negation
no
NCT02301962_exc_T7
Condition
active disease
NCT02301962_exc_T8
Temporal
for >=5 years prior to enrolment
NCT02301962_exc_T9
Reference_point
enrolment
NCT02301962_exc_T10
Mood
felt to be at low risk
NCT02301962_exc_T11
Condition
recurrence
NCT02301962_exc_T12
Qualifier
Adequately
NCT02301962_exc_T13
Condition
non-melanomatous skin cancer
NCT02301962_exc_T14
Procedure
treated
NCT02301962_exc_T15
Condition
lentigo maligna
NCT02301962_exc_T16
Condition
evidence of disease
NCT02301962_exc_T17
Negation
without
NCT02301962_exc_T18
Qualifier
Adequately
NCT02301962_exc_T19
Procedure
treated
NCT02301962_exc_T20
Condition
cervical carcinoma in situ
NCT02301962_exc_T21
Negation
without
NCT02301962_exc_T22
Condition
disease
NCT02301962_exc_T23
Scope
non-melanomatous skin cancer or lentigo maligna
NCT02301962_exc_T24
Condition
Prostatic intraepithelial neoplasia
NCT02301962_exc_T25
Condition
prostate cancer
NCT02301962_exc_T26
Negation
without
NCT02301962_exc_T27
Mood
evidence of
NCT02301962_exc_T28
Mood
evidence of
NCT02301962_exc_T29
Negation
except
NCT02301962_exc_T30
Scope
Malignancy treated with curative intent and with no known active disease present for >=5 years prior to enrolment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease; Adequately treated cervical carcinoma in situ without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer
NCT02301962_exc_T31
Condition
delayed hypersensitivity reaction
NCT02301962_exc_T32
Condition
mediate o persensitivity reaction o
NCT02301962_exc_T33
Condition
idiosyncrasy
NCT02301962_exc_T34
Drug
drugs chemically related to panitumumab
NCT02301962_exc_T35
Drug
ugs chemically related to panitumumab o cipients t
NCT02301962_exc_T36
Scope
drugs chemically related to panitumumab or excipients
NCT02301962_exc_T37
Procedure
i-epidermal growth factor receptor (E ibody therapy (e
NCT02301962_exc_T38
Drug
panitumumab
NCT02301962_exc_T39
Drug
cetuximab
NCT02301962_exc_T40
Scope
panitumumab or cetuximab
NCT02301962_exc_T41
Procedure
EGFr
NCT02301962_exc_T42
Procedure
treatment with small molecule EGFr inhibitors
NCT02301962_exc_T43
Drug
gefitinib
NCT02301962_exc_T44
Drug
erlotinib
NCT02301962_exc_T45
Drug
lapatinib
NCT02301962_exc_T46
Scope
gefitinib, erlotinib, lapatinib
NCT02301962_exc_T47
Procedure
Antitumor therapy
NCT02301962_exc_T48
Procedure
chemotherapy
NCT02301962_exc_T49
Procedure
hormonal therapy
NCT02301962_exc_T50
Procedure
immunotherapy
NCT02301962_exc_T51
Procedure
antibody therapy
NCT02301962_exc_T52
Procedure
radiotherapy
NCT02301962_exc_T53
Scope
chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy
NCT02301962_exc_T54
Drug
investigational agent
NCT02301962_exc_T55
Procedure
therapy
NCT02301962_exc_T56
Temporal
<=30 days before first dose of study treatment
NCT02301962_exc_T57
Condition
not recovered from any acute toxicity
NCT02301962_exc_T58
Reference_point
first dose of study treatment
NCT02301962_exc_T59
Scope
Antitumor therapy (e.g., chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy
NCT02301962_exc_T60
Temporal
<=30 days before study entry
NCT02301962_exc_T61
Qualifier
Other
NCT02301962_exc_T62
Procedure
investigational procedure
NCT02301962_exc_T63
Condition
interstitial lung disease
NCT02301962_exc_T64
Condition
ILD
NCT02301962_exc_T65
Condition
interstitial pneumonitis
NCT02301962_exc_T66
Condition
pulmonary fibrosis
NCT02301962_exc_T67
Mood
evidence of
NCT02301962_exc_T68
Condition
ILD
NCT02301962_exc_T69
Temporal
baseline
NCT02301962_exc_T70
Procedure
chest computer tomography
NCT02301962_exc_T71
Scope
interstitial pneumonitis, pulmonary fibrosis or evidence of ILD on baseline chest computer tomography
NCT02301962_exc_T72
Scope
interstitial lung disease (ILD)
NCT02301962_exc_T74
Condition
keratitis
NCT02301962_exc_T75
Condition
ulcerative keratitis
NCT02301962_exc_T76
Qualifier
severe
NCT02301962_exc_T77
Condition
dry eye
NCT02301962_exc_T78
Procedure
Major surgery
NCT02301962_exc_T79
Procedure
general anesthesia
NCT02301962_exc_T80
Temporal
<=30 days before first dose of study treatment
NCT02301962_exc_T81
Reference_point
first dose of study treatment
NCT02301962_exc_T83
Procedure
Minor surgical procedure
NCT02301962_exc_T84
Procedure
open biopsy
NCT02301962_exc_T85
Temporal
<=7 days before first dose of study treatment
NCT02301962_exc_T86
Reference_point
first dose of study treatment
NCT02301962_exc_T87
Negation
not yet
NCT02301962_exc_T88
Condition
recovered
NCT02301962_exc_T89
Temporal
prior
NCT02301962_exc_T90
Procedure
minor surgery
NCT02301962_exc_T91
Qualifier
Clinically significant
NCT02301962_exc_T92
Condition
cardiovascular disease
NCT02301962_exc_T93
Condition
myocardial infarction
NCT02301962_exc_T94
Condition
unstable angina
NCT02301962_exc_T95
Condition
congestive heart failure
NCT02301962_exc_T96
Qualifier
symptomatic
NCT02301962_exc_T97
Qualifier
serious
NCT02301962_exc_T98
Qualifier
uncontrolled
NCT02301962_exc_T99
Condition
cardiac arrhythmia
NCT02301962_exc_T100
Temporal
<=6 months prior to enrolment
NCT02301962_exc_T101
Reference_point
enrolment
NCT02301962_exc_T102
Scope
myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia
NCT02301962_exc_T103
Scope
Clinically significant cardiovascular disease
NCT02301962_exc_T105
Qualifier
Unstable
NCT02301962_exc_T106
Condition
pulmonary embolism
NCT02301962_exc_T107
Condition
deep vein thrombosis
NCT02301962_exc_T108
Qualifier
other
NCT02301962_exc_T109
Qualifier
significant
NCT02301962_exc_T110
Condition
us throm c event <=30 days be
NCT02301962_exc_T111
Condition
venous thromboembolic event
NCT02301962_exc_T112
Temporal
<=30 days before first dose of study treatment
NCT02301962_exc_T113
Reference_point
first dose of study treatment
NCT02301962_exc_T114
Scope
arterial/venous thromboembolic event
NCT02301962_exc_T115
Scope
Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event
NCT02301962_exc_T116
Procedure
anticoagulation
NCT02301962_exc_T117
Qualifier
stable
NCT02301962_exc_T118
Multiplier
therapeutic dose
NCT02301962_exc_T119
Temporal
prior to first dose of study treatment
NCT02301962_exc_T120
Reference_point
first dose of study treatment
NCT02301962_exc_T121
Condition
pregnant
NCT02301962_exc_T122
Observation
breast feeding
NCT02301962_exc_T123
Observation
become pregnant
NCT02301962_exc_T124
Temporal
during treatment
NCT02301962_exc_T125
Temporal
within 2 months after the discontinuation of study treatment
NCT02301962_exc_T126
Reference_point
the discontinuation of study treatment
NCT02301962_exc_T127
Reference_point
treatment
NCT02301962_exc_T128
Scope
during treatment and within 2 months after the discontinuation of study treatment
NCT02301962_exc_T129
Scope
pregnant or breast feeding, or planning to become pregnant
NCT02301962_exc_T130
Measurement
test(s) for human immunodeficiency virus infection
NCT02301962_exc_T131
Value
positive
NCT02301962_exc_T132
Condition
infection
NCT02301962_exc_T133
Temporal
Active
NCT02301962_exc_T134
Procedure
systemic treatment
NCT02301962_exc_T135
Condition
uncontrolled infection
NCT02301962_exc_T136
Temporal
<=14 days prior to first dose of study treatment
NCT02301962_exc_T137
Reference_point
first dose of study treatment
NCT02301962_exc_T138
Qualifier
any
NCT02301962_exc_T139
Scope
Active infection requiring systemic treatment or any uncontrolled infection
NCT02301962_exc_T140
Condition
urinary tract infection
NCT02301962_exc_T141
Qualifier
uncomplicated
NCT02301962_exc_T142
Negation
with the exception of
NCT02301962_exc_T143
Condition
upper respiratory tract infection
NCT02301962_exc_T144
Scope
uncomplicated urinary tract infection or upper respiratory tract infection
NCT02301962_exc_T146
Mood
planning to